Bacterial prodigiosins are red-colored secondary metabolites with multiple activities, such as anticancer, antimalarial and immunosuppressive, which hold great potential for medical applications. In this study, dramatically enhanced prodigiosins (RED) production in Streptomyces coelicolor was achieved by combinatorial metabolic engineering, including inactivation of the repressor gene ohkA, deletion of the actinorhodin (ACT) and calcium-dependent antibiotic (CDA) biosynthetic gene clusters (BGCs) and multi-copy chromosomal integration of the RED BGC. The results showed that ohkA deletion led to a 1-fold increase of RED production over the wild-type strain M145. Then, the ACT and CDA BGCs were deleted successively based on the ΔohkA mutant (SBJ101). To achieve multi-copy RED BGC integration, artificial ΦC31 attB site(s) were inserted simultaneously at the position where the ACT and CDA BGCs were deleted. The resulting strains SBJ102 (with a single deletion of the ACT BGC and insertion of one artificial attB site) and SBJ103 (with the deletion of both BGCs and insertion of two artificial attB sites) produced 1.9- and 6-fold higher RED titers than M145, respectively. Finally, the entire RED BGC was introduced into mutants from SBJ101 to SBJ103, generating three mutants (from SBJ104 to SBJ106) with chromosomal integration of one to three copies of the RED BGC. The highest RED yield was from SBJ106, which produced a maximum level of 96.8 mg g-1 cell dry weight, showing a 12-fold increase relative to M145. Collectively, the metabolic engineering strategies employed in this study are very efficient for the construction of high prodigiosin-producing strains.
Keywords: Streptomyces coelicolor; metabolic engineering; multi-copy integration; prodigiosins.